S A Plotkin

Summary

Affiliation: Aventis Pharma

Publications

  1. ncbi request reprint Conclusions to the conference on orphan vaccines
    S A Plotkin
    Aventis Pasteur, Doylestown, Philadelphia, PA 18901, USA
    Dev Biol (Basel) 110:167-9. 2002
  2. ncbi request reprint Vaccines in the 21st century
    Stanley A Plotkin
    Department of Pediatrics, University of Pennsylvania, Philadelphia, USA
    Hybrid Hybridomics 21:135-45. 2002
  3. ncbi request reprint Human cytomegalovirus vaccine is an orphan
    S A Plotkin
    Aventis Pasteur, Doylestown, Philadelphia, PA 18901, USA
    Dev Biol (Basel) 110:73-80. 2002
  4. ncbi request reprint Lessons learned concerning vaccine safety
    S A Plotkin
    Wistar Institute, University of Pennsylvania, Aventis Pasteur, 4650 Wismer Road, Doylestown, PA 18901, USA
    Vaccine 20:S16-9; discussion S1. 2001
  5. pmc Postscript relating to new allegations made by Edward Hooper at The Royal Society Discussion Meeting on 11 September 2000
    S A Plotkin
    University of Pennsylvania, Wistar Institute, 4650 Wismer Road, Doylestown, PA 18901, USA
    Philos Trans R Soc Lond B Biol Sci 356:825-9. 2001
  6. pmc Untruths and consequences: the false hypothesis linking CHAT type 1 polio vaccination to the origin of human immunodeficiency virus
    S A Plotkin
    University of Pennsylvania, Wistar Institute, 4650 Wismer Road, Doylestown, PA 18901, USA
    Philos Trans R Soc Lond B Biol Sci 356:815-23. 2001
  7. ncbi request reprint CHAT oral polio vaccine was not the source of human immunodeficiency virus type 1 group M for humans
    S A Plotkin
    University of Pennsylvania, Doylestown, PA, 18901, USA
    Clin Infect Dis 32:1068-84. 2001
  8. ncbi request reprint Immunologic correlates of protection induced by vaccination
    S A Plotkin
    Aventis Pasteur, Doylestown, PA 18901, USA
    Pediatr Infect Dis J 20:63-75. 2001
  9. ncbi request reprint Vaccines, vaccination, and vaccinology
    Stanley A Plotkin
    Department of Pediatrics, University of Pennsylvania, Philadelphia, and Aventis Pasteur, Doylestown, Pennsylvania, USA
    J Infect Dis 187:1349-59. 2003
  10. ncbi request reprint Is there a formula for an effective CMV vaccine?
    Stanley A Plotkin
    University of Pennsylvania, Wistar Institute, Aventis Pasteur, Doylestown, PA 18901, USA
    J Clin Virol 25:S13-21. 2002

Collaborators

  • S P Adler
  • J Desmyter
  • T Yoshikawa
  • S Luby
  • Peter Wutzler
  • Catherine Sadzot-Delvaux
  • Isabelle Parent Du Chatelet
  • Pierre Chauvin
  • Sadao Suga
  • Yoshizo Asano
  • Bernard Rentier
  • Anwar T Merchant
  • Joseph B McCormick
  • Tariq Moatter
  • Susan Fisher-Hoch
  • Mubina Agboatwalla
  • Daniel Ekra

Detail Information

Publications29

  1. ncbi request reprint Conclusions to the conference on orphan vaccines
    S A Plotkin
    Aventis Pasteur, Doylestown, Philadelphia, PA 18901, USA
    Dev Biol (Basel) 110:167-9. 2002
  2. ncbi request reprint Vaccines in the 21st century
    Stanley A Plotkin
    Department of Pediatrics, University of Pennsylvania, Philadelphia, USA
    Hybrid Hybridomics 21:135-45. 2002
  3. ncbi request reprint Human cytomegalovirus vaccine is an orphan
    S A Plotkin
    Aventis Pasteur, Doylestown, Philadelphia, PA 18901, USA
    Dev Biol (Basel) 110:73-80. 2002
  4. ncbi request reprint Lessons learned concerning vaccine safety
    S A Plotkin
    Wistar Institute, University of Pennsylvania, Aventis Pasteur, 4650 Wismer Road, Doylestown, PA 18901, USA
    Vaccine 20:S16-9; discussion S1. 2001
    ..Investigations that show the putative relationship to be incorrect serve as examples of scientific rigor, which are valuable for the public. The author draws eight lessons for the future from our recent experiences...
  5. pmc Postscript relating to new allegations made by Edward Hooper at The Royal Society Discussion Meeting on 11 September 2000
    S A Plotkin
    University of Pennsylvania, Wistar Institute, 4650 Wismer Road, Doylestown, PA 18901, USA
    Philos Trans R Soc Lond B Biol Sci 356:825-9. 2001
    ..These were proposed as conclusive evidence for the hypothesis that simian immunodeficiency virus-contaminated CHAT polio vaccine caused the HIV-1 group M epidemic. We have investigated the facts in relation to these 'smoking guns'...
  6. pmc Untruths and consequences: the false hypothesis linking CHAT type 1 polio vaccination to the origin of human immunodeficiency virus
    S A Plotkin
    University of Pennsylvania, Wistar Institute, 4650 Wismer Road, Doylestown, PA 18901, USA
    Philos Trans R Soc Lond B Biol Sci 356:815-23. 2001
    ..Testimony by eyewitnesses, documents of the time, epidemiological analysis, and ancillary phylogenetic, virologic and PCR data all concur to reject the hypothesis as false and without factual foundation...
  7. ncbi request reprint CHAT oral polio vaccine was not the source of human immunodeficiency virus type 1 group M for humans
    S A Plotkin
    University of Pennsylvania, Doylestown, PA, 18901, USA
    Clin Infect Dis 32:1068-84. 2001
    ..Testimony by eyewitnesses, historical documents of the time, epidemiological analysis, and analysis of ancillary phylogenetic, virological, and polymerase chain reaction data all indicate that this hypothesis is false...
  8. ncbi request reprint Immunologic correlates of protection induced by vaccination
    S A Plotkin
    Aventis Pasteur, Doylestown, PA 18901, USA
    Pediatr Infect Dis J 20:63-75. 2001
    ..A condition for the efficacy of antibodies is functionality, i.e. their ability to kill or inactivate pathogens. The immune system is redundant, and the different types of responses to vaccines act synergistically...
  9. ncbi request reprint Vaccines, vaccination, and vaccinology
    Stanley A Plotkin
    Department of Pediatrics, University of Pennsylvania, Philadelphia, and Aventis Pasteur, Doylestown, Pennsylvania, USA
    J Infect Dis 187:1349-59. 2003
  10. ncbi request reprint Is there a formula for an effective CMV vaccine?
    Stanley A Plotkin
    University of Pennsylvania, Wistar Institute, Aventis Pasteur, Doylestown, PA 18901, USA
    J Clin Virol 25:S13-21. 2002
  11. ncbi request reprint Safety and immunogenicity of the Towne strain cytomegalovirus vaccine
    S P Adler
    Department of Pediatrics, Medical College of Virginia Virginia Commonwealth University, Richmond 23298 0163, USA
    Pediatr Infect Dis J 17:200-6. 1998
    ..Women with naturally acquired serum antibodies to cytomegalovirus (CMV) are usually protected against both frequent secondary infection and giving birth to infants severely affected by intrauterine CMV infection...
  12. ncbi request reprint Vaccination against the major infectious diseases
    S A Plotkin
    University of Pennsylvania, Philadelphia, USA
    C R Acad Sci III 322:943-51. 1999
    ....
  13. ncbi request reprint Vaccines in the 21st century
    S A Plotkin
    Department of Pediatrics, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Infect Dis Clin North Am 15:307-27. 2001
    ..It is an optimistic vision, so let us hope that I am right...
  14. ncbi request reprint [New vaccination strategies]
    Stanley A Plotkin
    Sanofi Pasteur, 4650 Wismer Road, Doylestown, PA 18902, USA
    Bull Acad Natl Med 192:511-8; discussion 518-9. 2008
    ..Also, new methods of vaccine delivery besides injection will be used and new adjuvants will be added to vaccines in order to stimulate specific responses. The future of vaccination is promising...
  15. ncbi request reprint Commentary: congenital rubella syndrome should not be a disease of poor countries
    Stanley A Plotkin
    University of Pennsylvania and Aventis Pasteur, Doylestown, PA 18901, USA
    Pediatr Infect Dis J 23:1123-4. 2004
  16. ncbi request reprint Vaccines: past, present and future
    Stanley A Plotkin
    Sanofi Pasteur and the University of Pennsylvania, 4650 Wismer Road, Doylestown, Pennsylvania 18901, USA
    Nat Med 11:S5-11. 2005
    ..With all this come new problems in the production, regulation and distribution of vaccines...
  17. ncbi request reprint Congenital cytomegalovirus infection and its prevention
    Stanley A Plotkin
    Clin Infect Dis 38:1038-9. 2004
  18. ncbi request reprint Natural vs vaccine-acquired immunity to cytomegalovirus
    Stanley A Plotkin
    JAMA 290:1709; author reply 1709. 2003
  19. ncbi request reprint The history of rubella and rubella vaccination leading to elimination
    Stanley A Plotkin
    Department of Pediatrics, University of Pennsylvania, Philadelphia, PA, USA
    Clin Infect Dis 43:S164-8. 2006
    ..The present article summarizes the clinical syndrome of CRS, the process by which the vaccine was developed, and the history leading up to elimination, as well as the possible extension of elimination on a wider scale...
  20. ncbi request reprint Six revolutions in vaccinology
    Stanley A Plotkin
    University of Pennsylvania, Philadelphia, PA, USA
    Pediatr Infect Dis J 24:1-9. 2005
    ..I propose new delivery systems as the most likely to succeed, although humbly admitting that prediction is always subject to error...
  21. ncbi request reprint Why certain vaccines have been delayed or not developed at all
    Stanley A Plotkin
    University of Pennsylvania, Philadelphia, PA, USA
    Health Aff (Millwood) 24:631-4. 2005
    ..However, to take things further, there must be a vaccine manufacturer, a regulatory authority ready to give permission for the use of the vaccine, and public health authorities that will recommend and foster vaccination...
  22. doi request reprint Varicella vaccination in Japan, South Korea, and Europe
    Catherine Sadzot-Delvaux
    Unit of Fundamental Virology and Immunology, Department of Life Sciences, University of Liege, Sart Tilman, Belgium
    J Infect Dis 197:S185-90. 2008
    ..The recent development of a tetravalent vaccine against measles, mumps, rubella, and varicella could modify this variability in the future. It is evident that efforts to control varicella will spread gradually to all continents...
  23. doi request reprint Vaccines: correlates of vaccine-induced immunity
    Stanley A Plotkin
    Sanofi Pasteur, Doylestown, Pennsylvania, USA
    Clin Infect Dis 47:401-9. 2008
    ..In situations where the true correlate of protection is unknown or difficult to measure, surrogate tests (usually antibody measurements) must suffice as predictors of protection by vaccines. Examples of each circumstance are given...
  24. ncbi request reprint Of vaccination and infectious diseases in 2003
    Stanley A Plotkin
    University of Pennsylvania, USA
    Adv Exp Med Biol 549:1-4. 2004
  25. ncbi request reprint Chimpanzees and journalists
    Stanley A Plotkin
    Vaccine 22:1829-30. 2004
  26. ncbi request reprint Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules
    Isabelle Parent Du Chatelet
    Association pour l Aide a la Medecine Preventive, 25 rue du Dr Roux, 75724 Cedex 15, Paris, France
    Vaccine 21:1710-8. 2003
    ..Combined schedules of OPV and IPV in the form of diphtheria-pertussis-tetanus-IPV vaccine (DPT-IPV) may be useful to accelerate eradication of polio in developing countries...
  27. ncbi request reprint An epidemic of inhalation anthrax, the first in the twentieth century: I. Clinical features. 1960
    Stanley A Plotkin
    Am J Med 112:4-12; discussion 2-3. 2002
  28. ncbi request reprint The cost of not implementing routine neonates immunization programmes in HBsAg high prevalence countries
    Pierre Chauvin
    Vaccine 20:2848-50. 2002
  29. ncbi request reprint The late sequelae of Arrowsmith
    Stanley A Plotkin
    Medical and Scientific Advisor, Aventis Pasteur, Swiftwater, PA 18370, USA
    Pediatr Infect Dis J 21:807-9. 2002